Upgrade to SI Premium - Free Trial

Truist Securities on Eli Lilly (LLY): retatrutide ph3 results 'favorable' but similar data to Mounjaro

March 19, 2026 9:08 AM
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,281.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments